drugset / Trial / NCT03730337
Phase 1 Study of ONO-7475 With and Without ONO-4538 in Subjects Advanced or Metastatic Solid Tumors
Non-randomizedSingle-groupOpen-labelTreatment
Summary
To evaluate the tolerability and safety of ONO-7475 monotherapy and combinations with ONO-4538 in patients with advanced or metastatic solid tumors
Timeline
- Start
- 2018-10-17
- Primary completion
- 2021-06-28
- Completion
- 2022-11-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nivolumab | Monoclonal antibody | — | — |
| Subject | Tamnorzatinib | Small molecule | — | — |
Indications
No indication recorded.